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The aim of this study was to evaluate the cost-effective-
ness of a multifaceted implementation strategy for the 
prevention of hand eczema in comparison with a control 
group among healthcare workers. A total of 48 depart-
ments (n = 1,649) were randomly allocated to the imple-
mentation strategy or the control group. Data on hand 
eczema and costs were collected at baseline and every 
3 months. Cost-effectiveness analyses were performed 
using linear multilevel analyses. The probability of the 
implementation strategy being cost-effective gradually 
increased with an increasing willingness-to-pay, to 0.84 
at a ceiling ratio of €590,000 per person with hand ec-
zema prevented (societal perspective). The implementa-
tion strategy appeared to be not cost-effective in com-
parison with the control group (societal perspective), 
nor was it cost-beneficial to the employer. However, this 
study had some methodological problems which should 
be taken into account when interpreting the results. Key 
words: economic evaluation; implementation; hand ecze-
ma; healthcare workers; randomized controlled trial. 
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Healthcare workers handle many irritants in the course 
of their work, such as water, detergents and gloves (1, 
2). These irritants can damage the skin barrier function, 
which may lead to hand eczema (HE) (3). In a recent 
study, almost half of Dutch healthcare workers reported 
having symptoms related to HE (4). HE can have nega-
tive occupational consequences for the involved worker 
in terms of increased on-the-job productivity losses (i.e. 
presenteeism) (5), sick leave and increased turnover rates 
(5, 6). These negative occupational consequences have 
a large economic impact on employers and society as a 
whole. The annual societal costs of occupational HE are 
estimated to be approximately 9,000 €/patient (7). Most 
of these costs stem from the productivity losses associa-
ted with having HE, followed by healthcare costs (7). 
Considering the negative economic consequences of 
HE and its high prevalence among healthcare workers, 
prevention of HE among this population is of utmost im-
portance. To accomplish this goal, the Netherlands Society 
of Occupational Medicine (NVAB) developed a guideline 
for the prevention of HE in an occupational setting (8). A 
multifaceted implementation strategy was subsequently 
developed to implement this guideline among healthcare 
workers (9). This strategy was evaluated in a randomized 
controlled trial; the Hands4U study (9). Recently, the ef-
fects of the multifaceted implementation strategy on HE 
and preventive behaviour related to HE were evaluated, 
showing a positive effect on preventive behaviour and a 
negative effect on the prevalence of HE (10, 11).
Besides investigating the effects of an intervention, it 
is also important to investigate its financial consequen-
ces. This will give employers insight into the financial 
return of an occupational health intervention, which 
appeared to be a key deciding factor in the decision of 
whether to implement an intervention (12). This is of 
particular importance in the healthcare sector, where 
decision-makers are more inclined to invest their money 
in improving patient care rather than in improving the 
health of their own workers, as they are on a tight budget 
(12). The employer’s financial return for an intervention 
can be calculated by means of a return-on-investment 
(ROI) analysis. Health outcomes, however, are difficult 
to monetize and therefore cannot be included in a ROI 
analysis. Moreover, not only the employer may benefit 
from the intervention, but also other stakeholders (e.g. 
health insurance companies). Therefore, it is also im-
portant to perform cost-effectiveness analyses (CEAs) 
from the societal perspective, in which all costs are 
included irrespective of who pays or benefits from them.
The aim of the present study was, therefore, to ex-
plore the cost-effectiveness and financial return of the 
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multifaceted implementation strategy in comparison 
with a minimal implementation strategy. Cost-effective-
ness analyses were performed from both the societal and 
employer’s perspective. ROI analysis was performed 
solely from the employer’s perspective.
MATERIALS AND METHODS (for complete details 
see Appendix S11)
Methods
This study was performed alongside a 2-armed randomized 
controlled trial with 12 months follow-up. The study popula-
tion was recruited from several hospitals and nursing homes 
from different regions of the Netherlands. Departments were 
included as a whole and could participate if most workers within 
the department handled irritants during work. Randomization 
took place at the level of departments. The study protocol was 
approved by the medical ethics committee of the VU University 
Medical Center in Amsterdam (9). 
Intervention group: multifaceted implementation strategy. The 
intervention group received the multifaceted implementation 
strategy. This strategy contained the following components: 
education on (the prevention of) HE, participatory working 
groups, role models, reminders (posters), and a leaflet setting 
out the evidence-based recommendations from the guideline 
“Contact Dermatitis” of the NVAB (8). 
Control group. Workers in the control group received the same 
information leaflet as those in the intervention group. This 
leaflet was considered to be a minimal implementation strategy. 
Data collection.Baseline questionnaires were sent to all workers 
in the participating departments. Workers who completed the 
baseline questionnaire also received questionnaires at 3, 6, 9 
and 12 months follow-up. 
Baseline characteristics. The following variables were assessed 
at baseline: age (years), sec (male/female), number of working 
hours per week, number of working years in present job, having 
patient-related tasks (yes/no), education level (low/middle/
high), co-worker support, decision authority, having an atopic 
predisposition, and skin exposure to irritants in leisure time 
due to hobbies or care-related tasks outside work. A detailed 
description of these characteristics can be found elsewhere (11). 
Effect measures. The Nordic Occupational Skin Questionnaire 
– 2002 (NOSQ-2002) was used to measure the 3-month self-
reported prevalence of HE (13, 14). 
A partly modified version of the NOSQ-2002 was used to 
assess compliance with the NVAB guideline (13, 14). With 
this aim, a sum score was created, ranging from 0 to 5, where 
0 means that a participant did not comply with the NVAB 
guideline and 5 means that a participant fully complied with 
the NVAB guideline. 
Costs. Healthcare, absenteeism, and presenteeism were assessed 
at baseline, and after 3, 6, 9 and 12 months using questionnaires. 
Workers who indicated that they had (symptoms related to) 
HE during the previous 3 months were asked to complete a 
questionnaire assessing their utilization of primary healthcare 
(e.g. general practitioner, allied health professionals, comple-
mentary medicine), secondary healthcare (e.g. medical specia-
lists), and both prescribed and over-the-counter medications. 
Use of primary and secondary healthcare services was valued 
using Dutch standard costs (17). 
Sickness absence was measured using a slightly modified 
question of the PROductivity and DISease Questionnaire (PRO-
DISQ) (19), asking participants to report their total number of 
sick leave days due to HE during the previous 3 months. For the 
societal perspective, we estimated absenteeism costs by means 
of the Friction Cost Approach (FCA), with a friction period 
of 23 weeks and an elasticity of 0.8 (20). For the employer’s 
perspective, the Human Capital Approach (HCA) was used, 
in which costs are not truncated to the friction period and no 
elasticity factor is applied. 
A slightly modified version of the PRODISQ was used to 
assess productivity losses at work due to HE (i.e. presenteeism) 
(19). The questions from the PRODISQ measured the following: 
the number of days participants went to work while having HE 
during the previous 3 months; the quality of their work on those 
days measured on a 11-point scale (0: worst quality; 10: same 
quality as usual); and the amount of work that was performed 
on those days measured on a 11-point scale (0: could not do 
anything; 10: could do the same as usual). 
To estimate intervention costs, a bottom-up micro-costing 
approach was used. This means that detailed data were collected 
regarding the quantity of resources consumed as well as their 
unit prices (21). Intervention costs included all costs related to 
the implementation of the multifaceted implementation strategy. 
Statistical analyses
Analyses were performed according to the intention-to-treat 
principle. Descriptive statistics were used to compare baseline 
characteristics between the intervention and control group. 
Missing data were multiply imputed. Imputations were per-
formed per study group (intervention/control) using Predictive 
Mean Matching and Fully Conditional Specification in IBM 
SPSS (v20, Chicago, IL, USA). In total, 20 complete datasets 
were needed to reach a loss of efficiency below 5% (22, 23). 
Datasets were analysed separately, as specified below. Pooled 
estimates were subsequently calculated using Rubin’s rules 
(24). Cost-effectiveness analyses and ROI analyses were perfor-
med using Stata (V12, Stata Corp, College Station, TX, USA). 
We considered p < 0.05 as statistically significant. 
CEAs. CEAs were conducted using HE and the compliance 
measure as outcome measures from both the societal and 
employer’s perspective. Effectiveness at 12-month follow-up 
was analysed using linear multilevel analyses, adjusted for 
baseline values. A 2-level structure was used for all outcome 
measures (i.e. worker, department). Cost differences between 
study groups were calculated for total as well as disaggregated 
costs. Differences in costs were estimated using linear multi-
level analyses. To estimate 95% confidence intervals (95% 
CIs) around cost differences bias-corrected (BC) bootstrapping 
with 5,000 replications was used. Bootstrap replications were 
stratified for departments, to account for the clustering of data 
(25). Incremental cost-effectiveness ratios (ICERs) were cal-
culated by dividing the adjusted differences in costs by those in 
effects. Bootstrapped incremental cost-effect pairs (CE-pairs) 
were plotted on cost-effectiveness planes (CE-planes) (26). To 
provide a summary measure of the joint uncertainty of costs 
and effects, cost-effectiveness acceptability curves (CEACs) 
were constructed that show the probability of the intervention 
being cost-effective in comparison with usual care for a range 
of ceiling ratios (i.e. the maximum amount of money decision-
makers are willing to pay per unit of effect) (27). 
ROI analysis. ROI analysis was performed solely from the 
employer’s perspective. Within these analyses, costs were 
defined as intervention costs, and benefits as the difference 
in monetized outcome measures (i.e. absenteeism and presen-
teeism costs) between the control and intervention group during 1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2287
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follow-up, with positive benefits indicating reduced spending. 
Three ROI-metrics were calculated: (i) net benefits (NB); (ii) 
benefit cost ratio (BCR); and (iii) ROI (28–30). Subsequently, 
the probability of the intervention resulting in a positive fi-
nancial return to the employer was estimated by determining 
what proportion of bootstrapped ROI-estimates was positive 
(i.e. NB > 0, BCR > 1 and ROI > 0%) (28–30). 
Sensitivity analyses. Three sensitivity analyses were performed 
to assess the robustness of the results. In the first sensitivity 
analysis (SA1), The World Health Organization Health and 
Work Performance Questionnaire (WHO-HPQ) was used for 
estimating presenteeism costs (31, 32). In the second sensitivity 
analysis (SA2), absenteeism costs were valued using the HCA 
instead of the FCA for the societal perspective. In the third 
sensitivity analysis (SA3), presenteeism costs were excluded.
RESULTS
Participants
Of the 1,649 participants, 773 were allocated to the 
control group and 876 to the intervention group (see 
Fig. 1). Baseline characteristics of the study popula-
tion are described in Table I. There were some mea-
ningful differences between both groups for having 
a high level of education (control 52%; intervention 
57%), performing patient-related tasks (control 81%; 
intervention 69%) and having HE at baseline (control 
10%; intervention 7%). Of the 1,649 participants, 995 
(60%) completed the questions on HE at least 4 times 
(out of a total of 5), 593 (36%) completed at least 4 out 
of 5 cost questionnaires, and 1,153 (70%) completed 
the questions on the compliance measure at least 2 
out of 3 times. Participants with complete data were 
statistically significantly older and reported statisti-
cally significantly less often that they had an atopic 
predisposition than participants without complete data. 
These variables were included in the imputation model. 
Effectiveness and costs
At 12-month follow-up, no statistically significant 
differences were found in the presence of HE 
(–0.06; 95% CI –0.16–0.05) and in the compli-
ance measure (0.21; 95% CI –0.24–0.66) when 
comparing the intervention group with the 
control group. The costs of the multifaceted im-
plementation strategy were €114 per employee 
(see Table SI1). All costs were statistically 
significantly higher in the intervention group 
compared with the control group (Table SII1). 
The largest cost difference between the inter-
vention and control group was found for presen-
teeism costs (€2,764; 95% CI €2,478–3,057). 
Moreover, total costs in the intervention group 
were statistically significantly higher than in the 
control group from both perspectives (societal: 
€3,427; 95% CI €2,837–4,044; and employer’s: 
€3,318; 95% CI €2,649–4,035) (Table SIII1). 
Societal perspective: cost-effectiveness
The ICER for HE was –59,174 (Table SIII1), mea-
ning that the mean costs of the intervention to prevent 
an episode of HE in one participant were €59,174. 
The incremental CE-pairs were mainly located in the 
northeast quadrant of the CE-plane (74%), meaning 
that the intervention was more costly and more effec-
tive compared with the control group in preventing an 
episode of HE. The CEAC presented in Fig. S11 shows 
that the probability of the multifaceted implementation 
strategy being cost-effective in comparison with the 
control group was 0.06 if societal decision-makers are 
not willing to invest in the prevention of an episode of 
Table I. Baseline characteristics of the two study groups (n =1,649)a
Control 
(n = 773)
Intervention 
(n = 876)
Female, n (%) 603 (78.3) 683 (78.4)
Education*, n (%)
Low/middle 372 (48.3) 371 (42.6)
High 398 (51.7) 499 (57.4)
Age, years, mean (SD) 40.8 (11.3) 40.7 (11.5)
Working hours per week, mean (SD) 30.2 (8.8) 29.8 (8.1)
Years working at present company, mean (SD) 11.3 (9.9) 12.3 (10.7)
Patient related task (yes), n (%) 626 (81.2) 604 (69.4)
Colleague support, mean (SD) 3.1 (0.4) 3.1 (0.4)
Decision authority, mean (SD) 2.8 (0.5) 2.8 (0.4)
Being exposed to irritants outside work (yes), n (%) 673 (88.7) 774 (89.4)
Performing care related tasks outside work (yes), n (%) 309 (40.7) 369 (42.6)
Having an atopic predisposition (yes), n (%) 203 (26.4) 212 (24.5)
Hand eczema at baseline (yes), n (%) 80 (10.3) 64 (7.3)
aThe range of response rates for different aspects was 1,600–1,649 (96–100%).
Fig. 1. Participants in the trial based on the primary outcome measure.
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HE. This probability gradually increases with increasing 
values of willingness-to-pay, to a maximum of 0.84 at 
a ceiling ratio of €590,000. 
For the compliance measure, an ICER of 16,068 was 
found, meaning that for every 1-point improvement on 
the compliance measure, the intervention costs €16,068 
in comparison with the control group. The incremental 
CE-pairs were located mainly in the northeast quadrant 
of the CE-plane (77%), indicating that the interven-
tion was more costly and more effective in improving 
compliance compared with the control group. For the 
compliance measure, the probability of the strategy 
being cost-effectiveness was 0.06 if societal decision-
makers are not willing to invest in improving comp-
liance with the guideline “Contact Dermatitis”. This 
probability gradually increased with increasing values 
of willingness-to-pay, to a maximum of 0.82 at a ceiling 
ratio of €494,000.
Employer’s perspective: cost-effectiveness
The ICER for HE was –57,299 (see Table SIII1). This 
means that the costs of the intervention were €57,299 
for every episode of HE prevented in comparison with 
the control group. The incremental CE-pairs were lo-
cated mainly in the northeast quadrant of the CE-plane 
(71%), i.e. the intervention was more costly and more 
effective compared with the control group in preventing 
HE. From the employer’s perspective, the probability 
of the multifaceted implementation strategy being cost-
effective compared with the control group was 0.09 if 
employers are not willing to invest in the prevention of 
an episode of HE. The probability of the multifaceted 
implementation strategy being cost-effective in compa-
rison with the control group increases with an increasing 
willingness-to-pay, to a maximum of 0.84 at a ceiling 
ratio of €580,000.
An ICER of 15,559 was found for the compliance 
measure. This indicates that, compared with the control 
group, an improvement of one point on the compliance 
measure is associated with an additional cost of €15,559 
to the employer. The incremental CE-pairs were loca-
ted mainly in the northeast quadrant of the CE-plane 
(73%), suggesting that the intervention was more costly 
and more effective compared with the control group in 
improving compliance. The probability of the strategy 
being cost-effective was 0.09 if employers are not wil-
ling to invest in improving the compliance with the 
guideline “Contact Dermatitis”. This probability gra-
dually increased with an increasing willingness-to-pay, 
to a maximum of 0.82 at a ceiling ratio of €480,000. 
Employer’s perspective: financial return
The total intervention’s employer’s benefits, NB, BCR, 
and ROI were negative during follow-up, meaning that 
the investments were larger than the benefits (Table 
SIV1). The intervention’s probability of financial return 
was 0.12. 
Sensitivity analyses
The results of SA1, SA2 and SA3 differed to some 
extent from those of the main analyses. In SA1, the 
total cost difference was no longer statistically signi-
ficant from the employer’s perspective (€454; 95% CI 
–€452–€1,343) (Table SIII1). In addition, although the 
results of SA1 and SA3 pointed in the same direction 
as those of the main analyses, the costs were lower 
and the cost-effectiveness results from these analyses 
were therefore slightly more favourable (Tables SIII1 
and SIV1). Fig. S11 shows the CEACs from the societal 
perspective for SA1, SA2 and SA3. For SA1 and SA3, 
the CEAC were more favourable, as the probability 
that the intervention is cost-effective in comparison 
with the control group increases to a maximum of 0.85 
at ceiling ratios of €210,000 in SA1, and €190,000 in 
SA3. Furthermore, the probabilities of financial return 
to the employers were higher in SA1 and SA3 than for 
the main analysis, but still remained low, namely 0.36 
and 0.34, respectively. 
DISCUSSION
The multifaceted implementation strategy was not 
considered cost-effective from either the societal or 
employer’s perspective in comparison with the control 
group, as reasonable probabilities of cost-effectiveness 
were obtained only at very high willingness-to-pay va-
lues. It is highly unlikely that societal decision-makers 
or employers are willing to pay such large amounts of 
money per person prevented from having HE and/or 
per 1-point improvement on the compliance outcome. 
In addition, the employer’s investments for the strategy 
outweighed their benefits and the associated probability 
of financial return was low (i.e. 0.12). Thus, the inter-
vention was also not cost-beneficial to the employer.
Interpretation of the findings 
There may be several potential explanations for the 
multifaceted implementation strategy’s lack of cost-
effectiveness and financial return. First, the results 
showed that the difference in productivity-related 
costs between the intervention and control groups 
were large. The implementation strategy might have 
influenced the participants’ reporting of absenteeism 
and presenteeism due to HE, as those participating in 
the education sessions were made aware of the fact 
that their work could lead to HE. Making the workers 
more aware of this relationship might lead to more 
reporting of absenteeism and presenteeism related to 
HE. Secondly, workers might label their presenteeism 
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and absenteeism differently after the implementa-
tion strategy. In the Netherlands, there is no need for 
workers to indicate whether absenteeism and presen-
teeism is work-related, as workers receive sickness 
or disability benefits regardless of the nature of their 
complaints (33, 34). After the intervention, the workers 
might understand the connection between their health 
complaints and related absenteeism and presenteeism, 
and report future absenteeism and presenteeism in 
relation to HE. A third explanation for the findings 
of the present study could be related to the setting in 
which the trial was performed. We aimed to prevent 
HE among healthcare workers in the workplace. Ho-
wever, recent reviews on the financial return of work-
place wellness programmes concluded that there is no 
strong evidence of cost savings due to worksite health 
promotion programmes (35, 36). This lack of strong 
evidence might indicate that cost savings are difficult 
to establish when implementing primary prevention 
strategies in the workplace. Primary prevention con-
tinues to be difficult, as there is a long delay between 
the change in behaviour and the actual reward (better 
health) (37), making it difficult for people to continue 
their healthy behaviour. In addition, the cost savings 
of primary prevention might also be delayed, making 
it difficult to measure cost savings due to workplace 
health promotion programmes after just one year. 
It is noteworthy that the findings of the present study 
deviated slightly from those of the accompanying ef-
fectiveness paper (11); i.e. after 12 months, there was no 
statistically significant difference between the interven-
tion and usual care group regarding the prevalence of 
HE, whereas this difference was statistically significant 
in favour of the usual care group in the effectiveness 
paper. This difference can be explained by the fact that 
multiple imputation was used in the present study for 
the handling of missing data, whereas the effectiveness 
paper accounted for the missing data by using logistic 
multilevel analyses with random coefficients (38). 
Robustness of the results
Results from the sensitivity analyses resulted in slightly 
more favourable cost-effectiveness results than those 
of the main analyses due to smaller cost differences 
between the treatment groups. However, overall the 
conclusions regarding the cost-effectiveness of the 
multifaceted implementation strategy as well as its fi-
nancial return are in line with the main analyses. Some 
differences in results between the sensitivity analyses 
and the main analysis, however, are noteworthy. When 
the WHO-HPQ was used to estimate presenteeism costs 
instead of the modified-PRODISQ, the intervention 
was still not considered cost-effective in comparison 
with the control group, but cost differences were much 
smaller. This difference is probably explained by the 
fact that the WHO-HPQ and the PRODISQ concep-
tualize and measure presenteeism in different ways. 
The WHO-HPQ measures general work performance, 
whereas the modified-PRODISQ measures work per-
formance in relation to health complaints. In addition, 
the PRODISQ measures presenteeism by 2 questions, 
namely a question on the quality of work as well as 
its quantity, whereas the WHO-HPQ solely measures 
general work performance. We opted for the modified-
PRODISQ instead of the WHO-HPQ, because the 
PRODISQ’s conceptualization of presenteeism is most 
in line with the study by Zhang et al. (39), namely that 
health problems reduce both the quantity and quality 
of work. Furthermore, as HE was the primary interest 
of the study, measuring productivity in relation to HE 
seemed to be the most suitable choice compared with 
measuring general work performance. In addition, the 
costs for healthcare and absenteeism were also measu-
red in relation to HE, making it a logical choice also 
to measure productivity in relation to HE. On the other 
hand, the WHO-HPQ might be less influenced by an 
increased awareness of HE among study participants 
compared with the PRODISQ, as the WHO-HPQ mea-
sures general work performance without relating this 
work performance to HE. 
Strengths and limitations
This is the first study evaluating the cost-effectiveness 
of a multifaceted implementation strategy to prevent 
HE as well as its financial return in comparison with 
usual care. A strength of this study is that the risk of 
contamination between study groups was minimized by 
performing randomization at the level of departments. 
In addition, by performing linear multilevel analyses 
in combination with bootstrapping we were able to 
account both for the resulting clustering of data and 
the skewed distribution of cost data. 
A first limitation of this study is the amount of missing 
data. For example, only 40% of the study population 
completed at least 4 out of the 5 cost questionnaires. 
Although missing data were imputed using state-of-the-
art techniques, the results are probably less reliable and 
valid than when a complete dataset would have been 
obtained. Therefore, the results of the present study 
must be interpreted with caution. A second limitation is 
that all outcome measures were based on self-reports. 
As the multifaceted implementation strategy was de-
signed, among others, to increase awareness of HE and 
to explain how work could lead to HE, this might have 
influenced the reporting of the study participants, as 
argued above. Therefore, we cannot be sure whether 
our results are a reflection of the intervention or merely 
a product of increased awareness. A third limitation of 
the study was that medical costs were assessed only for 
workers who reported having HE (symptoms). Howe-
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ver, as the multifaceted implementation strategy was 
aimed at primary prevention, it is likely that participants 
in the intervention group without HE also purchased, 
for instance, moisturizers, in an effort to prevent HE. 
As a result, the medical costs in the intervention group 
might have been slightly underestimated. 
Implications for practice and/or research
First, there is a need for more economic evaluations 
in the field of HE (prevention). Only one earlier study 
investigated the economic consequences of a HE in-
tervention, in which the patients received integrated 
care (40). Giving organizations insight into financial 
implications of an intervention is considered to be im-
portant for the decision-making process about whether 
to invest in an intervention (12). Not performing an 
economic evaluation in our study would have led to 
a more positive recommendation regarding further 
implementation of the multifaceted implementation 
strategy, as our effect evaluation showed positive re-
sults regarding compliance with the NVAB guideline 
(10, 11). After the economic evaluation, we cannot 
recommend widespread implementation of the stra-
tegy without performing more research to investigate 
the effects. Therefore, we would recommend studies 
on HE to incorporate an economic evaluation in the 
study design. 
Conclusion
This economic evaluation showed that a multifaceted 
implementation strategy for the prevention of HE was 
not cost-effective in comparison with care as usual, 
from both the societal and employer’s perspective. In 
addition, it did not result in a positive financial return 
to the employer. 
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